TG6002 oncolytic vaccinia virus and chemotherapy synergy: a promising strategy for pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant cancer characterized by poor prognosis and limited treatment options, often associated with significant toxicity. Recently, we described TG6002, an oncolytic vaccinia virus (VACV) engineered for tumor-selective replication through the del...

Full description

Bibliographic Details
Published in:	Frontiers in Microbiology
Main Authors:	Johann Foloppe, Isabelle Farine, Christelle Pichon, Juliette Kempf, Julie Hortelano, Baptiste Moreau, Sandrine Cochin, Armelle Takeda, Patrick Pessaux, Philippe Erbs
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-09-01
Subjects:	pancreatic ductal adenocarcinoma oncolytic vaccinia virus TG6002 combination chemotherapy patient-derived tumor models
Online Access:	https://www.frontiersin.org/articles/10.3389/fmicb.2025.1656984/full

Similar Items

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
by: Jérémy Béguin, et al.
Published: (2020-12-01)

Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors
by: Jérémy Béguin, et al.
Published: (2023-09-01)

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
by: Franck Gallardo, et al.
Published: (2020-11-01)

Recent progress in combination therapy of oncolytic vaccinia virus
by: Seyedeh Nasim Mirbahari, et al.
Published: (2024-03-01)

Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
by: Mengyuan Li, et al.
Published: (2023-09-01)

Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12
by: Cheyne Kurokawa, et al.
Published: (2024-03-01)

Oncolytic vaccinia virus and cancer immunotherapy
by: Lihua Xu, et al.
Published: (2024-01-01)

Tachypleus tridentatus Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth
by: Gongchu Li, et al.
Published: (2018-06-01)

Dose Considerations for Vaccinia Oncolytic Virus Based on Retrospective Reanalysis of Early and Late Clinical Trials
by: Mefotse Saha Cyrelle Ornella, et al.
Published: (2024-09-01)

Advances of oncolytic vaccinia viruses armed with interleukin in tumor therapy
by: Mingyong Zha, et al.
Published: (2025-05-01)

Construction of three strains of recombinant oncolytic vaccinia virus and their anti-tumor activity
by: LI Dan-yang, FANG Jing-jing, TANG Hui
Published: (2020-04-01)

A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells
by: Yanrong Zhou, et al.
Published: (2023-01-01)

Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
by: Liu Liqiong, et al.
Published: (2022-06-01)

Oncolytic Vaccinia Virus Expressing <i>Aphrocallistes vastus</i> Lectin as a Cancer Therapeutic Agent
by: Tao Wu, et al.
Published: (2019-06-01)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
by: Cao-Sang Truong, et al.
Published: (2022-02-01)

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus
by: Claudia Hill, et al.
Published: (2021-06-01)

Haliotis discus discus Sialic Acid-Binding Lectin Reduces the Oncolytic Vaccinia Virus Induced Toxicity in a Glioblastoma Mouse Model
by: Gongchu Li, et al.
Published: (2018-04-01)

Development of the drug oncolytic immunotherapy based on vaccinia viruses <i>(Vaccinia virus, Orthopoxvirus, Chordopoxvirinae, Poxviridae)</i> against breast cancer
by: T. V. Bauer, et al.
Published: (2020-02-01)

Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer
by: Wenyi Yan, et al.
Published: (2025-04-01)

ROS Induced by <i>Aphrocallistes vastus</i> Lectin Enhance Oncolytic Vaccinia Virus Replication and Induce Apoptosis in Hepatocellular Carcinoma Cells
by: Yanan Zhang, et al.
Published: (2024-06-01)

pH Sensitive Erythrocyte-Derived Membrane for Acute Systemic Retention and Increased Infectivity of Coated Oncolytic Vaccinia Virus
by: Kaelan T. Samoranos, et al.
Published: (2022-08-01)

An Oncolytic Vaccinia Virus Expressing Aphrocallistes Vastus Lectin Modulates Hepatocellular Carcinoma Metabolism via ACSS2/TFEB-Mediated Autophagy and Lipid Accumulation
by: Qiang Wang, et al.
Published: (2025-07-01)

Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)
by: Shuguang Zuo, et al.
Published: (2021-02-01)

Design and Engineering of Deimmunized Vaccinia Viral Vectors
by: Kevin Song, et al.
Published: (2020-11-01)

Oncolytic Vaccinia Virus Expressing White-Spotted Charr Lectin Regulates Antiviral Response in Tumor Cells and Inhibits Tumor Growth In Vitro and In Vivo
by: Xue Wang, et al.
Published: (2021-05-01)

Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer models
by: Kyle G Potts, et al.
Published: (2017-03-01)

Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy
by: Xinjun Liu, et al.
Published: (2022-09-01)

A model of the artificial metastasis of human epidermoid carcinoma A431 in nude mice for examination of the oncolytic activity of vaccinia virus
by: G. V. Kochneva, et al.
Published: (2015-12-01)

Oncolytic Vaccinia Virus Harboring <i>Aphrocallistes vastus</i> Lectin Inhibits the Growth of Hepatocellular Carcinoma Cells
by: Riqing Jiang, et al.
Published: (2022-06-01)

Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma
by: Wei Wei, et al.
Published: (2024-12-01)

Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment
by: Jee Soo Park, et al.
Published: (2022-01-01)

Oncolytic Vaccinia Virus Carrying <i>Aphrocallistes vastus</i> Lectin (oncoVV-AVL) Enhances Inflammatory Response in Hepatocellular Carcinoma Cells
by: Xinnan Zheng, et al.
Published: (2022-10-01)

BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy
by: Jee Soo Park, et al.
Published: (2025-08-01)

GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer
by: Yujing Xuan, et al.
Published: (2025-01-01)

Oncolytic Virotherapy for Cancer: Clinical Experience
by: Shyambabu Chaurasiya, et al.
Published: (2021-04-01)

Oncolytic Vaccinia Virus Harboring <i>Aphrocallistes vastus</i> Lectin Inhibits the Growth of Cervical Cancer Cells Hela S3
by: Jiajun Ni, et al.
Published: (2021-09-01)

Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice
by: Hajime Kurosaki, et al.
Published: (2021-04-01)

A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer
by: Lijuan Chen, et al.
Published: (2025-01-01)

The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies
by: Qiaoyun Ling, et al.
Published: (2022-11-01)

Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response
by: Yasmin Shakiba, et al.
Published: (2023-06-01)